Diagnostic Kits/Patents limit medical potential of sequencing: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
AClearwater (talk | contribs)
No edit summary
m UTurn to 1287450000
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
Merz, J.F., 2002. Patents limit medical potential of sequencing. Nature, 419(6910), 878.
*Merz, J.F., 2002 - This brief comment by Merz makes two important points.  Quick and easy gene sequences will be limited because of patents and licensing.  First, some patent holders will not license their patents which will prevent a comprehensive test form being developed.  Second, given those that do license the amount of licenses required and the stacked royalty payments will make the test prohibitively expensive.
*Merz, J.F., 2002 - This brief comment by Merz makes two important points.  Quick and easy gene sequences will be limited because of patents and licensing.  First, some patent holders will not license their patents which will prevent a comprehensive test form being developed.  Second, given those that do license the amount of licenses required and the stacked royalty payments will make the test prohibitively expensive.



Latest revision as of 19:25, 12 May 2025

Merz, J.F., 2002. Patents limit medical potential of sequencing. Nature, 419(6910), 878.

  • Merz, J.F., 2002 - This brief comment by Merz makes two important points. Quick and easy gene sequences will be limited because of patents and licensing. First, some patent holders will not license their patents which will prevent a comprehensive test form being developed. Second, given those that do license the amount of licenses required and the stacked royalty payments will make the test prohibitively expensive.

Navigation

Main Page Diagnostic_Kits